Drug-induced sarcoidosis-like reaction (DISR) has been described to be associated with different classes of commonly used drugs. These medications are known to induce a systemic granulomatous inflammatory disorder considered to be clinically, biologically, radiologically, and microscopically indistinguishable from sarcoidosis. It occurs in a temporal relationship with the offending drug and can improve or resolve if the drug is discontinued. The most frequently used drugs that have been associated with DISR comprise the combination of antiretroviral therapy (cART), tumor necrosis factor alpha antagonists, interferons, and immune checkpoint inhibitors. Patients more commonly demonstrate pulmonary and cutaneous manifestations, while lymphadenopathy may be detected in approximately 5% of the cases. Other manifestations include fever, uveitis, hypercalcemia, cough, dyspnea, headache, weakness, and paresis. The oral manifestations of DISR are rare and more commonly associated with the use of Adalimumab, an antagonist of TNF alpha. Patients more often demonstrate painless diffuse swellings that may affect different regions of the oral mucosa, more frequently the gingival tissue, palate, cheek mucosa, and tongue. Although most cases are considered indolent, specific therapeutic approaches include the use of topical or systemic corticosteroids, methotrexate, infliximab, and hydroxychloroquine. Patients often demonstrate rapid resolution if the offending drug can be withdrawn, and overall prognosis is usually very good.